Nex Eye
Pioneering next-generation cancer immunotherapy with the ONCOKINE platform, targeting refractory cancer cells for enhanced treatment efficacy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
* | KRW22.0b | Series A | |
| Total Funding | 000k | ||
Related Content
NEX I is at the forefront of biotech innovation, specializing in advanced cancer immunotherapy. The company has developed a cutting-edge platform called ONCOKINE, which identifies and targets cancer cells that resist conventional treatments. This positions NEX I as a transformative player in the oncology sector.
NEX I serves a global market, focusing on healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around the development and commercialization of proprietary cancer therapies, leveraging its unique ONCOKINE platform. Revenue is generated through licensing agreements, partnerships, and direct sales of its therapeutic solutions.
The company's mission is to enhance the quality of life for cancer patients by providing more effective treatment options. By understanding the mechanisms of refractory cancers, NEX I aims to set a new standard in cancer care, offering hope to patients and their families.
Keywords: cancer immunotherapy, ONCOKINE, refractory cancer, biotech innovation, oncology, healthcare, therapeutic solutions, proprietary platform, global market, quality of life.